Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

The drug has promising data in hand in diffuse large B cell lymphoma ... Surveyor Capital, Logos Capital, EcoR1 Capital, Perceptive Advisors, Boxer Capital, Monashee Investment Management ...

The Jamestown Board of Public Utilities has found itself in the capable hands of David Leathers for 20 years. Amid all the uncertainty of New York’s energy policy Leathers has found a way to minimize ...

After hours: March 7 at 7:50:05 PM EST Loading Chart for TEVA ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

After hours: March 7 at 7:50:05 PM EST ...